EMA Authorised: Jinarc (tolvaptan) — Otsuka Pharmaceutical Netherlands B.V.

View source ↗

Summary

The EMA has authorised Jinarc (tolvaptan) for autosomal dominant polycystic kidney disease under the MAH Otsuka Pharmaceutical Netherlands B.V., with a decision…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• JINARC (tolvaptan)

Snippet

Status: Authorised. Therapeutic area: Polycystic Kidney, Autosomal Dominant. MAH: Otsuka Pharmaceutical Netherlands B.V.. Decision date: 07/08/2025